Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Wholesale Investor Conference 2012
16 slides from Anagenics's conference presentation, Nov 20, 2012
Slide 1: ASX Announcement: Cellmid CEO to present at Wholesale Investor Conference
ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE SYDNEY, Tuesday, 20 November 2012: Cellmid Limited (ASX: CDY) CEO, Maria Halasz, will present today at the Wholesale Investor Conference, held at 12:30pm at the MLC Centre in Sydney, NSW. A copy of the presentation is included
Slide 2: Cellmid: listed biotechnology company
• Listed biotechnology company (CDY. ASX) • Market cap $9 million • Base burn rate $150K per month before revenue • Multiple near term revenue from OTC and diagnostic products Maria Halasz CEO [email protected]
Slide 3: Forward-looking statements
This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual res
Slide 4: Cellmid
Cellmid Significant near term revenue – OTC and diagnostics Strong product pipeline Track record in execution and delivery www.cellmid.com.au 3
Slide 5: Significant near term revenue - OTC
Significant near term revenue ‐ OTC • evolis hair growth products with TGA listed claims: • Promotes hair growth • Helps reduce hair loss and thinning • Helps restore the natural growth cycle of the hair by inhibiting FGF‐5 • Australian manufactured • Launched in June 2012 • 700 chemists already sec
Slide 6: First clinically validated hair growth product in 24 years
First clinically validated hair growth product in 24 years Annual sales: Monoxidil $300M* Finasteride (Propecia) $1,097.6M* *Newport Horizon 5
Slide 7: évolis vs Competitor
évolis® vs Competitor évolis Competitor No reported side effects, very safe due to clear Poor side effect profile, including lethargy and mode of action depression with long term use No initial shedding Initial shedding often occurs, benefits take 3‐4 months to start Newly grown hair continues to gr
Slide 8: Clinical study results
Clinical study results Quantitative assessment • Rate of hair growth increased by 21% • Hair loss reduced by 35% Qualitative assessment • 74% found the treatment beneficial for hair growth 7
Slide 9: Distribution
Distribution 700 pharmacies Australian pharmacy by EOY 2012 sales 25% of pharmacies (1,300) by EOY 2013 Direct sales force Australian (commissioned agents) direct sales to Targeting 210 salons Advangen hairdressers by EOY 2013 International Group buying deals and évolis website Electronic media and
Slide 10: Powerful patent position with strong product pipeline
Powerful patent position with strong product pipeline PRECLINICAL CLINICAL MARKET évolis® hair growth products MK‐ELISA (research market) MK metastatic colorectal diagnostic MK hepatocellular carcinoma diagnostic MK antibodies for inflammation and cancer MK for heart attack 9
Slide 11: Diagnostics pipeline
Diagnostics pipeline • License 1: Quest (Celera) lung cancer screening test • Product expected on market in mid 2013 • Milestone payments and royalties due on launch • License 2: Pacific Edge Diagnostics bladder cancer test • Product expected on market in 2013 • Milestone payments and royalties due
Slide 12: Therapeutics pipeline
Therapeutics pipeline Animal studies Preclinical DISEASE Reduced Disease reduced by MK treatment? Clinical indication Disease in RNAi mAbs and/or MK validation Mdk‐/‐? Inhibitors YES Osteosarcoma Cancer nd (multiple YES 50% Glioma/glioblastoma cancers) Metastasising carcinomas Surgical Abdominal sur
Slide 13: Track record in execution and delivery
Track record in execution and delivery Dr David King Graeme Kaufman Martin Rogers Maria Halasz 12
Slide 14: Recent highlights
Recent highlights • Sept 2012 Distribution target exceeded with 700 pharmacies within 3 months • Sept 2012 Exclusive Australian distributor appointed for évolis • July 2012 US ischemia patent allowed, 4th granted in the same patent group • June 2012 Cellmid’s Midkine Conference with 70 scientists at
Slide 15: Cellmid
CELLMID • Significant near term revenue – OTC and diagnostics • Strong product pipeline • Track record in execution and delivery 14
Slide 16: Thank you
Thank you www.cellmid.com.au Maria Halasz CEO (612) 9299 0311 halasz@cellmid com.au 15